NEW YORK (GenomeWeb News) – Genewiz and the John Theurer Cancer Center at Hackensack University Medical Center today announced a collaboration for the discovery of ovarian cancer biomarkers.
The deal is aimed at identifying biomarkers from ovarian cancer samples that can be used to predict a patient's prognosis, as well as the outcomes from chemotherapy treatments. The cancer center will supply the samples for analysis at Genewiz's CLIA laboratory in South Plainfield, NJ.
"Genewiz's cutting-edge genomic analysis technologies and informatics capabilities, including our recently launched OncoGxOne Discovery ovarian cancer panel, enable us to comprehensively assay ovarian cancer-related genes for the detection of all types of genomic aberrations, including gene fusions and copy number variance, in addition to indels and point mutations," Shihong Li, Genewiz's principal investigator said in a statement.
Financial and other details were not disclosed.
The announcement follows yesterday's deal between Genewiz and KeyTest Diagnostics to develop molecular diagnostics for the Chinese market.